Business Description
Nascent Biotech Inc
NAICS : 325412
SIC : 2834
ISIN : US63108Q1013
Description
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is actively engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.99 | |||||
| Equity-to-Asset | 0.05 | |||||
| Debt-to-Equity | 4.17 | |||||
| Debt-to-EBITDA | -0.11 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 57.1 | |||||
| 3-Year EPS without NRI Growth Rate | 35.1 | |||||
| 3-Year FCF Growth Rate | 2.1 | |||||
| 3-Year Book Growth Rate | 46.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.69 | |||||
| 9-Day RSI | 44.1 | |||||
| 14-Day RSI | 43.2 | |||||
| 6-1 Month Momentum % | 26.8 | |||||
| 12-1 Month Momentum % | 209.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.05 | |||||
| Quick Ratio | 1.05 | |||||
| Cash Ratio | 1.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -43.2 | |||||
| Shareholder Yield % | 0.01 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -404.8 | |||||
| ROIC % | -296.76 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -14.17 | |||||
| EV-to-EBITDA | -14.17 | |||||
| EV-to-FCF | -13.47 | |||||
| Earnings Yield (Greenblatt) % | -7.06 | |||||
| FCF Yield % | -7.21 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:NBIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nascent Biotech Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.015 | ||
| Beta | -3.14 | ||
| Volatility % | 148.78 | ||
| 14-Day RSI | 43.2 | ||
| 14-Day ATR ($) | 0.013153 | ||
| 20-Day SMA ($) | 0.112859 | ||
| 12-1 Month Momentum % | 209.05 | ||
| 52-Week Range ($) | 0.0323 - 0.28 | ||
| Shares Outstanding (Mil) | 169.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nascent Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nascent Biotech Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nascent Biotech Inc Frequently Asked Questions
What is Nascent Biotech Inc(NBIO)'s stock price today?
The current price of NBIO is $0.10. The 52 week high of NBIO is $0.28 and 52 week low is $0.03.
When is next earnings date of Nascent Biotech Inc(NBIO)?
The next earnings date of Nascent Biotech Inc(NBIO) is .
Does Nascent Biotech Inc(NBIO) pay dividends? If so, how much?
Nascent Biotech Inc(NBIO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers